Create an Account
  1. Home
  2. Specialty
  3. Retina

VBS Fellows’ Foray 2023 – Retina’s Believe It or Not: Case-Based Examples and Real-World Treatment Strategies

VBS Fellows Foray 2023 Retinas Believe It or Not CaseBased Examples and RealWorld Treatment Strategies
Media formats available:
Details

  • Overview

    Carefully selected cases are presented by fellows from around the globe. Retina cases you would not believe! Real-world treatment strategies are enthusiastically discussed among the esteemed panel members. This truly unique series is designed for fellows, residents, and eye care specialists who recently entered practice and are involved in the management of patients with vitreoretinal disorders. This content was captured during a live symposium. Voting took place during the symposium. 

     

    This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc. and Carl Zeiss Meditec.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Summarize the practical utility of different imaging modalities and their use for diagnosing and monitoring retinal pathologies
    • Recognize key pathological features of various retinal conditions that may affect treatment outcomes
    • Evaluate patients to determine the treatment approach or combination of approaches (steroid, anti-VEGF, surgical) that would be most appropriate for managing disease presentation
    • Formulate troubleshooting guides to mitigate the effect of unexpected intraoperative vitreous behavior
    • Apply case study examples to real-world clinical settings.

    • Accreditation

      This educational activity is provided by Evolve Medical Education LLC (Evolve).

      Accreditation Statement
      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

    • Faculty and Disclosures

      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      VBS Board Moderators:

      Yewlin E. Chee, MD
      Associate Professor of Ophthalmology
      University of Washington Department of Ophthalmology
      Seattle, WA

      Anton Orlin, MD
      Associate Professor of Ophthalmology
      Weill Cornell Medical College
      New York, NY

      D. Wilkin Parke III, MD
      VitreoRetinal Surgery, PA Co-director
      Vitreoretinal Surgery Fellowship Program
      Minneapolis, MN

      Aleksandra V. Rachitskaya, MD
      Assistant Professor of Ophthalmology
      Cole Eye Institute, Cleveland Clinic
      Cleveland, OH

      Panelists:

      Fellows:

       

      DISCLOSURE POLICY

      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
      The following faculty members and planning committee have the following financial relationships with ineligible companies.

      Surbhi Agrawal, MD, has had no financial relationships or affiliations with an ineligible company.

      Sruthi Arepalli, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: EyePoint Pharmaceuticals. 

      Yewlin E. Chee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon.

      Natasha Ferreira Santos da Cruz, MD, has had no financial relationships or affiliations with an ineligible company.

      Vaidehi S. Dedania, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Character Bio, EyePoint Pharmaceuticals, Iveric Bio, Regeneron, and Spark Therapeutics.

      Samuel Feldman, MD, has had no financial relationships or affiliations with an ineligible company.

      Peter K. Kaiser, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX Therapeutics, Aviceda, Bayer, Bausch + Lomb, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Coherus, Complement Therapeutics, DelSiTech, Dompé, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Genentech/Roche, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kodiak Sciences, Kriya Therapeutics, Nanoscope Therapeutics, Novartis, Ocugenix, Ocular Therapeutix, Oculis, Ocuphire Pharma, OcuTerra, Omeros, Oxurion, Palatin, Regeneron, Regenxbio, Resonance Medicine, RetinaAI Medical AG, Retinal Sciences, Roivant, Samsung Bioepis, SGN Nanopharma, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa Pharma, and Unity Biotechnology.

      Thomas Lazzarini, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech and Regenxbio.

      Jennifer Hyuna Kim Lee, MD, has had no financial relationships or affiliations with an ineligible company.

      Gabriela LópezCarasa, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon and Allergan. Speaker's Bureau: Alcon.

      Almira Manzano, MD, has had no financial relationship or affiliation with an ineligible company.

      Sonia Mehta, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Merck.

      John B. Miller, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Carl Zeiss Meditec, Genentech, Sunovion, and Topcon.

      Rachel S. Mogil, MD, has had no financial relationships or affiliations with an ineligible company.

      Jennifer Nadelmann, MD, has had no financial relationships or affiliations with an ineligible company.

      Michael D. Ober, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: I-Lumen.

      Anton Orlin, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant/Advisory Board: Allergan, Carl Zeiss Meditec, EyePoint Pharmaceuticals, and Genentech.

      D. Wilkin Parke III, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech and Regenxbio. Royalties: Vortex Surgical.

      Aleksandra V. Rachitskaya, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Apellis, Carl Zeiss Meditec, Iveric Bio, Genetech, and Regeneron. Grant/Research Support: AGTC, DRCR.net Retina Network, and Genentech. Speaker's Bureau: Apellis, Genentech, and Regeneron.

      Margaret McDougal Runner, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, and Alimera Sciences, and Allergan.

      Patrick Staropoli, MD, has had no financial relationships or affiliations with an ineligible company.

      Matthew Starr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Genentech, Gryoscope Therapeutics, and Regenxbio.

      Katherine E. Talcott, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Apellis, EyePoint Pharmaceuticals, and Genentech. Speaker's Bureau: Genentech and Iveric Bio. Grant/Research Support: Carl Zeiss Meditec and Regenxbio.

      Edward Wood, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Genentech, Pharming, and Regenxbio. Patents/Royalties: Vortex Surgical. Speaker's Bureau: Iveric Bio. Shareholder: Quadrant Eye.

      Camila Ventura, MD, PhD, has had no financial relationships or affiliations with an ineligible company.

      The Evolve staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Regeneron Pharmaceuticals, Inc., or Carl Zeiss Meditec.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free